Deal management software for life sciences developers

What makes a life sciences pipeline different

Life sciences deals are decided by building physics before they are decided by price. A wet lab tenant needs structural floor loads and vibration performance beyond office standards, taller floor-to-floor heights to route mechanical and plumbing distribution, heavy outside-air and exhaust capacity, redundant power, and provisions for chemical storage. A building that fails those criteria cannot be negotiated into working. So the first screen in a lab pipeline is physical, and it kills most candidates.

That is true whether the team is ground-up developing or converting. The conversion case, buying office or flex product and repositioning it for lab users, adds a layer: the deal underwrite is really a scope underwrite. What does it cost to get this specific structure, this specific mechanical space, this specific power service to lab standard? The answer comes from structural and MEP consultants, which means a lab deal accumulates engineering reports the way a multifamily deal accumulates rent comps.

Two more traits shape the workflow. Tenant improvement intensity: lab TI packages run multiples of office TI, dominated by mechanical, electrical, and plumbing scope, so TI exposure is a first-order underwriting input rather than a rounding item. And geography: this business concentrates in a handful of cluster markets anchored by research institutions, above all Boston, the San Francisco Bay Area, and San Diego, which means most teams run deep pipelines in two or three metros rather than shallow pipelines in ten.

The stage list reflects all of it: sourcing, physical screening, consultant diligence, underwriting and scope pricing, LOI, contract and full due diligence, close, then conversion or construction, and lease-up against a tenant base whose credit is tied to venture funding cycles.

A worked example: a converter's screen in San Diego

Consider a converter evaluating six buildings in San Diego for lab repositioning. The physical screen runs first: floor load capacity, floor-to-floor height, available mechanical space, structural bay spacing, and power service. Four of the six fail on some combination of those criteria and die before anyone builds a model. That is the correct outcome, and it only happens reliably when the screening fields are recorded per deal rather than debated from memory.

The two survivors now generate real diligence spend. Each needs a structural review, an MEP assessment, and a zoning read on lab use, call it $40,000 to $80,000 in consultant reports per building before the team can price conversion scope with confidence. Those reports, their findings, and the deadlines they feed (LOI response dates, contract contingency periods) are now the deal.

The underwriting discipline comes from the market data. With top-13-market lab vacancy at 23.2% and new construction carrying vacancy far higher, a converter's lease-up assumptions have to be defended against vintage-level evidence, and the deals that pencil are the ones in proven submarkets at a basis the spreadsheet-era competition cannot reconstruct. A team that can pull last quarter's MEP findings, current scope pricing, and the diligence calendar for both live deals in one view makes that call with its eyes open.

Market context: a bifurcated recovery

The life sciences market in mid-2026 is two markets wearing one label. The headline numbers are hard: lab and R&D vacancy across the top 13 U.S. markets rose to 23.2% in Q1 2026, per CBRE, with average asking rents down a fifth consecutive quarter to $67.30 per sq. ft. NNN and nine of 13 major markets posting negative absorption. Bisnow reports the roughly 60 million sq. ft. of labs completed between 2020 and 2025 carried 55.6% vacancy, with the 2025 vintage at 73.4% and 34 buildings sitting entirely vacant since 2023.

The demand side has turned. JLL reports tenant demand across the top four markets (Boston, the Bay Area, San Diego, and Raleigh-Durham) surged 44% year over year to nearly 8 million sq. ft. in Q1 2026, with lab availability down about 2 million sq. ft. since mid-2025. CBRE recorded record biotech R&D employment and $7.4 billion of venture funding in Q1, the strongest trailing year since 2022.

The structural signals matter most for developers. JLL counts over 6.2 million sq. ft. of lab space already converted to other asset classes, shrinking supply, while lease terms for direct relocations compressed to 62 months, about 30% shorter than at the market peak. And the tenant base is widening: AI, robotics, and tough tech companies took 30% of Boston lab leases in 2025. The read for a development or conversion team: activity is returning, but it is concentrating in proven clusters and the best physical product, which makes deal selection the whole game.

Tool fit for a life sciences development team

The lab-specific requirement is the paper trail. A conversion deal is built on consultant findings, and six months after closing, someone will need to know exactly what the MEP assessment said about air handling capacity on the third floor. If that answer lives in a consultant's PDF in someone's inbox, the team pays to rediscover it.

How MotionCRE maps to a life sciences workflow

MotionCRE gives a lab development or conversion team the deal layer the spreadsheet was faking.

The pipeline board runs custom stages, so the board reads Sourcing, Physical Screen, Consultant Diligence, Underwriting, LOI, Contract and DD, Close, Conversion, Lease-Up, with days-in-stage showing where deals stall. Each building opens into a deal workspace with 50-plus standard fields, and custom fields hold the physical screen: floor load, floor-to-floor height, mechanical space, power service. A deal killed on the physical screen keeps its record, so the same building resurfacing through a different broker a year later takes five minutes to dismiss instead of a week.

Due diligence checklists run across eight categories, including environmental and zoning, which carry real weight in lab conversions. Task templates trigger on stage entry, so a deal reaching Consultant Diligence automatically generates the structural, MEP, and zoning work orders with assignees and due dates. Files keep every consultant report versioned inside the deal, and AI Associate answers questions from those files directly. Key dates track LOI responses and contingency deadlines, contacts hold the consultant, broker, and institutional counterparty relationships per deal, and deal rooms give capital partners a controlled document view during raises.

Pricing starts at $249 per month for 3 seats on the Team plan, with a 14-day free trial with full access. A credit card is required and you can cancel anytime.

Where to go deeper

Life sciences shares a spine with the other technical asset classes: the deal is gated by infrastructure diligence that generates documents, deadlines, and specialist counterparties. See how the same pattern plays out at higher voltage in deal management for data center developers and across land-driven pipelines in deal management for industrial developers. For the category basics, start with what deal management software is.